Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pirtobrutinib in Relapsed/Refractory and Treatment-Naïve CLL/SLL
NCT06588478Phase 2Recruiting
- Sponsor
- Loxo Oncology
- Start
- Jan 2025
- Primary completion
- Jun 2028
- Modality
- Small Molecules
- Countries
- 18
01
Overview
Phase 2, randomised, open-label trial of pirtobrutinib in chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) (4 arms), sponsored by Loxo Oncology. Primary endpoint: Overall Response Rate at 3 years. Started Jan 2025; status: recruiting.
02
Drugs
pirtobrutinib
03
Conditions
chronic lymphocytic leukemia (CLL)small lymphocytic lymphoma (SLL)
Beyond the preview
Go deeper on NCT06588478.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06588478.